“ RYR plus conventional therapy ” exhibited significant lowering effects on serum total cholesterol ( TC ) , low-density lipoprotein cholesterol ( LDL-C ) , and CRP but exhibited no significant effect on systolic BP , diastolic BP , triglycerides ( TG ) , and high-density lipoprotein cholesterol ( HDL-C ) compared with “ placebo plus conventional therapy . ” “
RYR plus conventional therapy ” showed significant lowering effects on systolic BP , TC , LDL-C , and CRP but no effect on diastolic BP , TG , and HDL-C compared with “ placebo plus conventional therapy . ”
No significant difference in BP and lipid profile between “ RYR plus conventional therapy ” and “ statins plus conventional therapy ” was observed .
“ RYR plus statins ” appeared to be more effective in lowering BP , TC , TG , and LDL-C but without a significant difference in HDL-C compared to statins .
No serious adverse events were reported .
The results of this meta- analysis suggested some supportive but limited evidence regarding RYR for hypertension .
ABSTRACT Interest is increasing regarding the potential health effects of red yeast rice ( RYR ) consumption , which is described as a “ natural statin ” in China .
This review aims to evaluate the efficacy of RYR on blood pressure ( BP ) , lipid profile , and C-reactive protein ( CRP ) in treating  hypertension .
Long-Term Effects of Xuezhikang on Blood Pressure in Hypertensive Patients with Previous Myocardial Infarction: Data from the Chinese Coronary Secondary Prevention Study (CCSPS)
Several previous trials from Western population studies have showed that statins may help reduce blood pressure ( BP ) . However , r and omized clinical data is limited . Xuezhikang , a partially extract of red yeast rice , contains a family of naturally occurring statins , and has a marked impact on lipids , but it is unknown whether Xuezhikang has any effect on BP during long-term follow-up in the Chinese population . This is a post-hoc subgroup analysis of a r and omized , double-blinded , placebo-controlled , parallel group clinical trial , Chinese Coronary Secondary Prevention Study ( CCSPS ) . A total of 2704 hypertensive patients with previous myocardial infa rct ion ( MI ) were assigned either to placebo ( n = = 1341 ) or to Xuezhikang ( n = = 1363 ) daily for an average of 4.5 years . The primary outcome was the unadjusted changes in mean arterial pressure ( MAP ) from baseline to 6 months . We also assessed systolic blood pressure ( SBP ) , diastolic blood pressure ( DBP ) , and pulse pressure . Analysis of covariance was used to calculate the adjusted effects of treatment on changes in these outcomes at 6 , 12 , 24 , and 48 months post-r and om- ization , after controlling for potential confounders . This analysis included 2704//4870 ( 55.5%% ) hypertensive patients for whom BP was measured at baseline and at least one follow-up visit after r and omization . Median duration of the follow-up was 4.5 years ( 54 months ) , and 25 patients ( 0.92%% ) were lost to the last follow-up because of adverse effects . The results showed that the unadjusted and adjusted changes in MAP , SBP , DBP , or pulse pressure from baseline were not significantly different for Xuezhikang or placebo recipients at 6 , 12 , 24 , and 48 months after r and omization . In this post-hoc subgroup analysis , we failed to demonstrate any significant reducing effects of Xuezhikang on BP in Chinese hypertensive patients with previous MI , suggesting that further prospect i ve study on the effects of statins on BP would be needed , especially in high-risk patients
“ RYR plus conventional therapy ” exhibited significant lowering effects on serum total cholesterol ( TC ) , low-density lipoprotein cholesterol ( LDL-C ) , and CRP but exhibited no significant effect on systolic BP , diastolic BP , triglycerides ( TG ) , and high-density lipoprotein cholesterol ( HDL-C ) compared with “ placebo plus conventional therapy . ” “
RYR plus conventional therapy ” showed significant lowering effects on systolic BP , TC , LDL-C , and CRP but no effect on diastolic BP , TG , and HDL-C compared with “ placebo plus conventional therapy . ”
No significant difference in BP and lipid profile between “ RYR plus conventional therapy ” and “ statins plus conventional therapy ” was observed .
“ RYR plus statins ” appeared to be more effective in lowering BP , TC , TG , and LDL-C but without a significant difference in HDL-C compared to statins .
No serious adverse events were reported .
The results of this meta- analysis suggested some supportive but limited evidence regarding RYR for hypertension .
ABSTRACT Interest is increasing regarding the potential health effects of red yeast rice ( RYR ) consumption , which is described as a “ natural statin ” in China .
This review aims to evaluate the efficacy of RYR on blood pressure ( BP ) , lipid profile , and C-reactive protein ( CRP ) in treating  hypertension .